IL1B and systemic-onset juvenile idiopathic arthritis: IL-1β may be selectively inhibited by canakinumab, a fully human monoclonal antibody which is actively used in rheumatologic disorders, such as systemic juvenile idiopathic arthritis and Still’s disease.